Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose continuous panobinostat for relapsed or refractory osteosarcoma, neuroblastoma, and MRT/ATRT
ACTRN12618000321246Phase 2Completed
- Sponsor
- Australia & New Zealand Children’s Haematology and Oncology Group
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in osteosarcoma (OS), neuroblastoma, malignant rhabdoid tumor (MRT) and 1 more, sponsored by Australia & New Zealand Children’s Haematology and Oncology Group. Primary endpoints: Clinical Benefit Rate by MRI/CT and Safety. Started Jan 2019; status: completed.
02
Drugs
panobinostat
03
Conditions
osteosarcoma (OS)neuroblastomamalignant rhabdoid tumor (MRT)Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on ACTRN12618000321246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000321246.